AI-powered ECG test for early cardiac amyloidosis
Part of Heart & circulation clinical trials.
This trial tests if an AI can spot early signs of cardiac amyloidosis from a standard 10-second ECG. If successful, it could lead to faster diagnosis and treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a digital ECG recording that is at least 10 seconds long.
- You do not have a paced rhythm (a pacemaker-driven heartbeat) on your ECG.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses an AI tool to look at your ECG (a simple heart test) to help find early signs of atrial fibrillation (an irregular heartbeat) or structural heart disease (changes in heart structure). It aims to see if the AI can help doctors catch these conditions sooner, even in people who don't yet have symptoms.
This study uses artificial intelligence (AI) to look at your heart tests (ECG and echo) and find people who might have a specific heart muscle disease called ATTR-CM. The goal is to catch it earlier so treatment can start sooner.
This study uses special heart tests (AI-ECG and CT scan) to look for a hidden condition called cardiac amyloidosis, which can affect people with atrial fibrillation. Finding it early may help guide treatment and improve outcomes.
This trial tests an AI program that looks at your heart ultrasound (echocardiogram) to find possible signs of cardiac amyloidosis early. It helps doctors decide if more testing is needed.
This study at Mayo Clinic is testing an artificial intelligence (AI) tool that analyzes echocardiograms (ultrasound of the heart) to find early signs of four types of heart muscle disease. If the AI flags a high-risk pattern, doctors can learn whether acting on that alert helps catch the condition sooner.
This trial uses an AI program to review ECG heart-tracing data collected from short-term monitoring devices. It aims to see whether the AI can better detect concerning heart rhythm patterns in people who are high risk for heart rhythm or heart problems.
Hear when a new Transthyretin Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.